Combined treatment with erythropoietin and granulocyte colony-stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction

Chinese Medical Journal

Volumn 127, Issue 9, 2014, Pages 1677-1683

  Xue, Jingyi ^a   Du, Guoqing ^a   Shi, Jing ^a   Li, Yue ^a   Masahiro, Yasutake ^b   Liu, Lei ^a   Li, Jianqiang ^a   Kong, Yihui ^a   Wang, Shuxian ^a   Yun, Fengxiang ^a   Li, Weimin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Acute myocardial infarction; Endothelial progenitor cells mobilization; Erythropoietin; Granulocyte colony stimulating factor; Neovascularization

Indexed keywords

CD34 ANTIGEN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; SPRAGUE DAWLEY RAT;

ANIMALS; BLOTTING, WESTERN; CHEMOKINE CXCL12; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; MALE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84899759994     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132764     Document Type: Article

References (35)

1. Kuswardhani RA, Soejitno A. Bone marrow-derived stem cells as an adjunctive treatment for acute myocardial infarction: a systematic review and meta-analysis. Acta Med Indones 2011; 43: 168-177.
2. Okada H, Takemura G, Kosai K, Tsujimoto A, Esaki M, Takahashi T, et al. Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure. Am J Physiol Heart Circ Physiol 2009; 296: H616-H626.
3. Delewi R, Nijveldt R, Hirsch A, Marcu CB, Robbers L, Hassell ME, et al. Left ventricular thrombus formation after acute myocardial infarction as assessed by cardiovascular magnetic resonance imaging. Eur J Radiol 2012; 81: 3900-3904.
4. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008; 10: 22-29.
5. Sanganalmath SK, Abdel-Latif A, Bolli R, Xuan YT, Dawn B. Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. Basic Res Cardiol 2011; 106: 709-733.
6. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Med 2005; 11: 305-311.
7. Kastrup J, Ripa RS, Wang Y, Jørgensen E. Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy? Eur Heart J 2006; 27: 2748-2754.
8. Brunner S, Huber BC, Weinberger T, Vallaster M, Wollenweber T, Gerbitz A, et al. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction. J Cell Mol Med 2012; 16: 152-159.
9. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-413.
10. Rigolin GM, Porta MD, Ciccone M, Bugli AM, Bragotti LZ, Mauro E, et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 2004; 126: 501-507.
11. Ding L, Dong L, Chen X, Zhang L, Xu X, Ferro A, et al. Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction. Circulation 2009; 120: 764-773.
12. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7.
13. Yao Y, Sheng Z, Li Y, Yan F, Fu C, Li Y, et al. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther 2012; 23: 1-12.
14. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012; 7 Suppl 1: S29-S34.
15. Ripa RS. Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease. Dan Med J 2012; 59: B4411.
16. Li Y, Fukuda N, Yokoyama S, Kusumi Y, Hagikura K, Kawano T, et al. Effects of G-CSF on cardiac remodeling and arterial hyperplasia in rats. Eur J Pharmacol 2006; 549: 98-106.
17. Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, Dimmeler S. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010; 105: 389-397.
18. Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 2006; 20: 956-958.
19. Werneck-de-Castro JP, Costa-E-Sousa RH, de Oliveira PF, Pinho-Ribeiro V, Mello DB, Peçanha R, et al. G-CSF does not improve systolic function in a rat model of acute myocardial infarction. Basic Res Cardiol 2006; 101: 494-501.
20. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
21. Yang J, Xia J, He Y, Zhao J, Zhang G. MSCs transplantation with application of G-CSF reduces apoptosis or increases VEGF in rabbit model of myocardial infarction. Cytotechnology 2013 Nov 20. Epub ahead of print.
22. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010; 74: 2365-2371.
23. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450.
24. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006; 98: 1405-1413.
25. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100: 662-669.
26. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011; 147: 124-131.
27. Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, van Halteren HK, et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 2009; 131: 285-287.
28. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20: 135-141.
29. Talan MI, Latini R. Myocardial infarction: cardioprotection by erythropoietin. Methods Mol Biol 2013; 982: 265-302.
30. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514.
31. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007; 28: 2018-2027.
32. Wang YB, Liu YF, Lu XT, Yan FF, Wang B, Bai WW, et al. Rehmannia glutinosa extract activates endothelial progenitor cells in a rat model of myocardial infarction through a SDF-1 α/CXCR4 cascade. PLoS One 2013; 8: e54303.
33. Chen F, Liu Q, Zhang ZD, Zhu XH. Co-delivery of G-CSF and EPO released from fibrin gel for therapeutic neovascularization in rat hindlimb ischemia model. Microcirculation 2013; 20: 416-424.
34. Bjorndahl M, Cao R, Eriksson A, Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ Res 2004; 94: 1443-1450.
35. Yeghiazarians Y, Khan M, Angeli FS, Zhang Y, Jahn S, Prasad M, et al. Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J Card Fail 2010; 16: 669-678.